SECURITIES AND EXCHANGE COMMISSION
13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
| Prenetics Global Limited | ||||||||
| By: | /s/ Lo Hoi Chun | |||||||
| Name: | Lo Hoi Chun | |||||||
| Title: | Chief Financial Officer | |||||||
| Date: July 11, 2024 | ||||||||
| Prenetics Global Limited | ||||||||
| By: | /s/ Lo Hoi Chun | |||||||
| Name: | Lo Hoi Chun | |||||||
| Title: | Chief Financial Officer | |||||||
| Date: July 11, 2024 | ||||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/11/2026 | $36.00 | Buy | Roth Capital |
| 1/18/2023 | $7.00 | Overweight | Cantor Fitzgerald |
| 7/12/2022 | Buy | Citigroup |
Roth Capital initiated coverage of Prenetics Group Ltd. with a rating of Buy and set a new price target of $36.00
Cantor Fitzgerald initiated coverage of Prenetics Group Ltd. with a rating of Overweight and set a new price target of $7.00
Citigroup initiated coverage of Prenetics Group Ltd. with a rating of Buy
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced it will release financial results for the fourth quarter and full year 2025 ended December 31, 2025 before market open on Wednesday, February 18, 2026. The Company will also hold its earnings conference call the same day at 10:00 a.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts. Date:Wednesday, February 18, 2026Time:10:00 a.m. Eastern TimeDial-in:1-877-425-9470International Dial-in:1-201-389-0878
Company Continues Portfolio Optimization on the Heels of Successful $72 million ACT Genomics sale Company Maintains Strong Balance Sheet with over $70 million in Cash and Cash Equivalents, 510 BTC and Zero Debt, representing approximately $118 million in Total Liquidity CHARLOTTE, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced that it has completed the sale of its 3PL distribution business operated by its subsidiary, Europa Sports Partners. The all-stock transaction is valued at up to $13 million, subject to the achieve
CHARLOTTE, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced an update to its previously announced voluntary warrant exchange program. Updated Participation and Impact In connection with the Company's prior financing round in October 2025, 2,722,642 Class A ordinary shares were issued, with one Class A warrant and one Class B warrant issued for each such Class A ordinary share, for a total of 5,445,284 warrants. As of the date of this announcement, the Company has entered into exchange agreements covering 4,720,832 of the
6-K - Prenetics Global Ltd (0001876431) (Filer)
6-K - Prenetics Global Ltd (0001876431) (Filer)
6-K - Prenetics Global Ltd (0001876431) (Filer)
- Prenetics adopts proven corporate Bitcoin strategy inspired by MicroStrategy's ~$40B Bitcoin holdings and Metaplanet's meteoric treasury transformation - Following strategic divestiture, Prenetics leverages strengthened $117M balance sheet to execute comprehensive Bitcoin strategy with board-approved majority allocation, institutional financing partnerships, and alpha-generating initiatives. CHARLOTTE, N.C., June 18, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading health sciences company, today announced it has become the first healthcare company to establish a Bitcoin treasury, completing a $20 million Bitcoin purchase of 187.42 BTC at an averag
LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, welcomes Kathryn M. Henry and David Vanderveen as independent directors to the Company's Board of Directors. "We are excited to welcome Kathryn and David to Prenetics' Board of Directors at this pivotal juncture," said Danny Yeung, CEO of Prenetics. "Their unparalleled expertise in consumer and health sectors, combined with their proven leadership in driving global expansion and operational excellence, will significantly enhance shareholder value as we expand into consumer health and wellness." "I am thrilled to join Prenetics at such a p
(From left: Dr. Ghada Alsaleh, Sonia Pawelczyk, Danny Yeung, Dr. James L. Green, Ahmed Alfandi, Dr. Tara Ruttley, Wasim Ahmed, Dr. Hilde Stenuit, Dr. Camille Alleyne at the MOU signing ceremony in Dubai, UAE Space Agency) Initial research project is with NDORMS, Botnar Research Institute, University of Oxford, focusing on accelerated aging in spaceDr. James L. Green, former Chief Scientist of NASA and Dr. Tara Ruttley, former Associate Chief Scientist of NASA to join Prenetics Scientific Advisory BoardInaugural research cube scheduled to be sent on-board SpaceX to the ISS in Q4 of 2024 DUBAI, United Arab Emirates, Feb. 09, 2024 (GLOBE NEWSWIRE) -- UAE Space Agency – Prenetics Global Li
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced it will release financial results for the fourth quarter and full year 2025 ended December 31, 2025 before market open on Wednesday, February 18, 2026. The Company will also hold its earnings conference call the same day at 10:00 a.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts. Date:Wednesday, February 18, 2026Time:10:00 a.m. Eastern TimeDial-in:1-877-425-9470International Dial-in:1-201-389-0878
Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 - $200M FY 2026 Revenue, $25M Monthly Revenue or $300M ARR by Year End 2026 IM8 Delivers 60% Gross Margin, 3.9 Months Payback Period, Demonstrating Strong Unit Economics Company to Host Earnings Call Today at 8:30am ET, Releases Inaugural Quarterly Shareholder Letter CHARLOTTE, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced third quarter 2025 financial
CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced it will release financial results for the third quarter 2025 ended September 30, 2025 before market open on Monday, November 10, 2025. The Company will also hold its first ever earnings conference call the same day at 8:30 a.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts. Date:Monday, November 10, 2025Time:8:30 a.m. Eastern TimeDial-in:1-844-425-9470International Dial-in:201-298-0878WebcastPRE Conference Call An audio replay of the webcast will
SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)
SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)
SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)